Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry

被引：0

作者：

Despoina-Rafailia Benetou

Charalampos Varlamos

Dionysios Ktenas

Ioannis Tsiafoutis

Michael Koutouzis

Theodora Bampali

Christos Mantis

John Zarifis

Emmanouil Skalidis

Dionysios Aravantinos

Dimitrios Varvarousis

Ioannis Lianos

John Kanakakis

Evangelos Pisimisis

Antonios Ziakas

Periklis Davlouros

Dimitrios Alexopoulos

机构：

[1] National and Kapodistrian University of Athens Medical School,2nd Department of Cardiology, Attikon University Hospital

[2] Patras University Hospital,Cardiology Department

[3] Hellenic Red Cross General Hospital,Cardiology Department

[4] University Hospital of Ioannina,Department of Cardiology

[5] Konstantopoulion Hospital,Department of Cardiology

[6] George Papanikolaou General Hospital,Cardiology Department

[7] Heraklion University Hospital,Department of Cardiology

[8] Sismanoglio-Amalia Fleming General Hospital of Athens,Department of Cardiology

[9] Asklepeion Hospital,Cardiology Department

[10] “Alexandra” University Hospital,Department of Clinical Therapeutics

[11] “Tzaneio” General Hospital of Piraeus,Department of Cardiology

[12] Aristotle University of Thessaloniki,Department of Cardiology, AHEPA University Hospital

来源：

Cardiovascular Drugs and Therapy | 2021年 / 35卷

关键词：

Atrial fibrillation; Percutaneous coronary intervention; Coronary stenting; Antithrombotic therapy; Antiplatelets; Anticoagulants;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：11 / 20

页数：9

共 556 条

[1]

Morillo CA(2017)Atrial fibrillation: the current epidemic J Geriatr Cardiol 14 195-203

[2]

Banerjee A(2019)Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation J Mark Access Health Policy 7 1574541-35

[3]

Perel P(2018)Patients with atrial fibrillation and coronary artery disease - double trouble Adv Med Sci 63 30-260

[4]

Wood D(2018)2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J 39 213-3767

[5]

Jouven X(2019)Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials Eur Heart J 40 3757-536

[6]

Coleman CI(2018)Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American Perspective-2018 Update Circulation. 138 527-e151

[7]

Briere JB(2019)2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society Circulation. 140 e125-165

[8]

Fauchier L(2019)2018 ESC/EACTS Guidelines on myocardial revascularization [published correction appears in Eur Heart J. 2019 Oct 1;40(37):3096] Eur Heart J 40 87-196

[9]

Levy P(2018)Contemporary antithrombotic treatment in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: rationale and design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry Cardiovasc Drugs Ther 32 191-1524

[10]

Bowrin K(2019)Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation N Engl J Med 380 1509-536

← 1 2 3 4 5 6 7 8 9 10 →